A rare manifestation in anti-phospholipid syndrome
DOI:
https://doi.org/10.18203/2394-6040.ijcmph20250942Keywords:
Recurrent pregnancy loss, Antiphospholipid syndrome, Subdural haematoma, Venous thrombosis, Bad obstetric historyAbstract
Pregnancy per se is a state of immuno suppression and hypercoagulability. When associated with auto immune disorders, we encounter life threatening situations. Antiphospholipid syndrome still represents an important treatable cause of pregnancy morbidity. Known for its systemic arterial and venous thrombotic manifestations. There exist a complexity and heterogeneity of the mechanisms beyond the poor obstetric outcome in APS. Thrombotic events in these patients consist in deep vein thrombosis (32%), stroke (13%), superficial thrombophlebitis (9%), pulmonary embolism (9%) and transient ischemic attack (7%), among other clinical manifestations. Stroke is the most frequent arterial thrombosis. Rarely, APS can manifest in the form of hemorrhage. We encountered Subdural haematoma in pregnancy which is an infrequent manifestation. Our patient had gone through all bitter experiences on account of APS mentioned in domain 4-obstetric: prefetal death, fetal death, preeclampsia with severe features, central nervous system dysfunction, placental insufficiency with severe features. She has prosthetic aortic valve and on anticoagulants. This pregnancy she reported in emergency room with subdural haematoma and miscarriage with the multidisciplinary team work we were able to treat the uncommon manifestation successfully. Embarking on pregnancy in future after a critical episode is debatable. In certain situations, the decision making is vital to minimize the morbidity.
Metrics
References
Hughes GRV. The antiphospholipid syndrome: ten years on. Lancet. 342;6:341-4. DOI: https://doi.org/10.1016/0140-6736(93)91477-4
Roubey RAS, Hoffman M. From antiphospholipid syndrome to antibody-mediated thrombosis. Lancet. 1997;350:1491-3. DOI: https://doi.org/10.1016/S0140-6736(05)63936-0
Gómez-Puerta JA, Cervera R. Diagnosis and classification of the antiphospholipid syndrome. J Autoimmun. 2014;8:20-5. DOI: https://doi.org/10.1016/j.jaut.2014.01.006
Yelnik CM, Laskin CA, Porter TF. Lupus anticoagulant is the main predictor of adverse pregnancy outcomes in aPL positive patients: validation of PROMISSE study results. Lupus Sci Med. 2016;3:13. DOI: https://doi.org/10.1136/lupus-2015-000131
Cervera R, Piette JC, Font J. antiphospholipid syndrome: Clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum. 2002;46:1019–27. DOI: https://doi.org/10.1002/art.10187
Erkan D, Asherson RA, Espinosa G, Cervera R, Font J, Piette JC, et al. Long term outcome of catastrophic antiphospholipid syndrome survivors. Ann Rheum Dis. 2003;62:5300-3. DOI: https://doi.org/10.1136/ard.62.6.530
Makatsariyaa AD, Khizroevaa J, Bitsadzea VO. Catastrophic antiphospholipid syndrome (Ronald Asherson syndrome) and obstetric pathology. J Perinat Med. 2018;46:387–400. DOI: https://doi.org/10.1515/jpm-2017-0092
Hakman E, Mikhael S. Clinical report of probable catastrophic antiphospholipid syndrome in pregnancy. Case Rep. Obstet. Gynecol. 2018;4:17645-6. DOI: https://doi.org/10.1155/2018/4176456
Oliveira I, Sampaio Rocha-Filho PA. Headache and systemic lupus erythematosus: a narrative review. Headache. 2023;63(4):461–71. DOI: https://doi.org/10.1111/head.14501